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In malaria-endemic Africa, human 
immunodeficiency virus (HIV) infec-
tion and malaria conspire to threaten 
maternal health: in some regions, nearly 
12% of women are coinfected with HIV 
and malaria parasites during pregnancy 
[1–4]. Both HIV infection and antenatal 
malaria individually increase the risks 
of miscarriage, stillbirth, preterm deliv-
ery, and intrauterine growth retardation 
[1,5]; these effects are amplified because 
HIV also exacerbates the harmful effects 
of antenatal malaria for the mother and 
fetus [5]. In women not infected with 
HIV, these harmful effects can be par-
tially mitigated by intermittent preven-
tive treatment in pregnancy (IPTp) with 
sulfadoxine-pyrimethamine (SP), which 
is broadly recommended throughout 
sub-Saharan Africa. However, HIV-
infected women typically take daily pre-
ventive therapy composed of another 
antifolate combination with antimalarial 
activity, trimethoprim-sulfamethoxazole 
(TMP-SMX), which is presumed to pro-
vide adequate if not equivalent protection 
against pregnancy malaria as SP. The evi-
dence base for the efficacy of TMP-SMX 
is poor [1], and the specific risks that 
malaria poses to HIV-infected pregnant 
women suggest the need for enhanced 
chemoprevention.
A recent multicountry trial involving 
HIV-infected pregnant women in East 
and Southern Africa highlighted the lim-
ited efficacy of TMP-SMX. Compared 
with daily TMP-SMX alone, the addi-
tion of monthly mefloquine as IPTp in 
addition to daily TMP-SMX reduced the 
risks of clinical malaria, malarial infec-
tion at delivery, and hospital admissions 
[6]. Unfortunately, mefloquine prophy-
laxis was not well tolerated and was also 
associated with increased maternal HIV 
load and mother-to-child transmission of 
HIV [6]. Other options to enhance IPTp 
have been explored in HIV-uninfected 
women but have been poorly tolerated 
or not efficacious and are therefore also 
unlikely to be suitable for HIV-infected 
women. These options included IPTp with 
the fixed-dose combination of chloro-
quine-azithromycin and IPTp with amo-
diaquine (alone or combined with SP) [7, 
8]. The search for alternative strategies for 
the prevention of malaria in HIV-infected 
women remains an urgent priority.
In this issue of The Journal of Infectious 
Diseases, Natureeba et  al report the 
results of the first exploratory trial evalu-
ating the impact in HIV-infected women 
of IPTp with dihydroartemisinin-piper-
aquine (DP) [9]. DP is an effective and 
well-tolerated candidate for IPTp. As an 
artemisinin-based combination therapy 
(ACT), DP is currently recommended by 
the World Health Organization (WHO) 
for the case management of malaria in 
the second and third trimesters. A recent 
comparison of 4 different fixed-dose 
ACTs for the case-management of malaria 
in pregnancy showed that DP had the 
best efficacy and an acceptable safety pro-
file, with an additional benefit of a longer 
post-treatment prophylactic effect, which 
supports its suitability as a candidate for 
IPTp in high transmission areas [10, 11]. 
This was confirmed in 2 recent explor-
atory trials in HIV-uninfected women 
in areas with high SP resistance in Kenya 
and Uganda, showing that IPTp with 
DP was much more effective than SP in 
reducing malaria infection and clinical 
malaria [12, 13]. Five similar IPTp trials 
with DP in HIV-uninfected women are 
ongoing or are scheduled to start soon for 
further safety assessment and to deter-
mine whether this reduction in malarial 
infection translates into improvements in 
pregnancy outcome.
Natureeba et  al enrolled 200 
HIV-infected pregnant women 
receiving efavirenz (EFV)–based 
antiretroviral therapy (ART) and using 
insecticide-treated nets in Uganda into a 
double-blinded, placebo-controlled trial 
to compare the effect of daily TMP-SMX 
alone versus monthly DP when given in 
addition to daily TMP-SMX. The pri-
mary end point was placental malarial 
infection, assessed by histopathologic 
analysis (active or past infections). 
Nearly all women had WHO stage 1 
HIV disease and 56% of women had 
HIV loads below the limit of detection. 
The study was conducted at the same site 
as their previous trial with DP as IPTp 
in HIV-negative women in which, com-
pared with SP as IPTp, DP reduced the 
risk of this same primary outcome by 
nearly half [13].
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In contrast to the previous trial in HIV-
uninfected women, the risk of placental 
infections in this new trial was very low 
in both arms, and, compared with that 
in the TMP-SMX–only arm, the risk was 
slightly but not significantly higher in the 
DP plus TMP-SMX arm (3.1% vs 6.1%; 
P = .5). This prevalence of placental infec-
tions was approximately 10-fold lower 
than the risk observed in HIV-infected 
daily TMP-SMX recipients in the pre-
vious years in this same study area [14]. 
Secondary outcomes determined using 
loop-mediated isothermal amplification 
to detect only actively infected placen-
tae came to similar conclusions, with 1 
infection detected in the TMP-SMX arm 
and 3 infections detected in the DP plus 
TMP-SMX arm. Overall, DP provided 
no additional benefit for malaria che-
moprevention in HIV-infected pregnant 
women beyond that provided by daily 
TMP-SMX.
Why did DP confer no additional 
benefit? First, as the authors note, the 
low prevalence of placental malarial 
infection reflects the remarkable drop in 
malaria transmission observed follow-
ing the introduction of indoor-residual 
insecticide spraying in the study district 
around the time study enrollment began. 
This effectively undermined the ability 
to measure differences in efficacy against 
a rare outcome. In addition, it cannot be 
excluded that, despite the high levels of 
parasite cross-resistance to antifolates in 
the study area, the protection achieved 
with daily TMP-SMX may be greater than 
that achieved by IPTp with SP: while SP 
is taken intermittently starting in the sec-
ond trimester, often with gaps of several 
weeks in between courses when reinfec-
tions can establish, TMP-SMX is taken 
daily and also throughout pregnancy, 
including prior to conception and in the 
first trimester. This intensive schedule 
could potentially enhance effectiveness 
by overcoming partial resistance and by 
protecting women early in pregnancy, 
when most new placental infections 
occur. Last, as the authors note in a recent 
companion article published elsewhere, 
the combination of pregnancy and EFV-
based ART can potentially induce metab-
olism of both dihydroartemisinin (by 
UDP-glucuronosyltransferases) and pip-
eraquine (by CYP isoenzymes) [15]. In 
this companion article, compared with 
HIV-uninfected pregnant women, preg-
nant women receiving EFV-based ART 
had reductions of 27% in the dihydroarte-
misinin area under the curve (AUC) 0–8 
hours and 38% in the piperaquine AUC 
0–21  days [15]. The lower exposure to 
both dihydroartemisinin and piperaquine 
suggests that dose adjustments of this 
fixed-dose combination may be needed in 
this group. While this current trial used a 
fixed dose of 3 tablets of DP for all women 
per the manufacturer’s recommendations, 
the use of recent weight-based dosage 
recommendations from the WHO would 
have rendered a large proportion (approx-
imately 50%) of the women (ie, those 
weighing ≥60 kg) taking 4 or 5 tablets.
Despite these negative results, the study 
demonstrates one pivotal finding for puta-
tive preventive medications: in women who 
also received daily EFV-based ART, the 
addition of monthly DP to daily TMP-SMX 
appears to be well tolerated. Furthermore, 
the details provided in the companion 
article suggested there were no indications 
that the piperaquine-associated corrected 
QT prolongations were worse in HIV-
infected women receiving TMP-SMX and 
EFV-based ARTs than in HIV-uninfected 
women receiving DHA-PIP and were also 
not associated with pregnancy status or, 
importantly, with the number of previous 
IPTp courses taken [15].
Based on this study alone, it would be 
wrong to conclude that HIV-infected 
women require no additional antena-
tal malaria prevention beyond daily 
TMP-SMX. The power of this study was 
undermined by the low prevalence of the 
primary outcome, which was unexpected 
and beyond the control of the investigators 
yet undoubtedly beneficial to the partici-
pants and their offspring. Encouragingly, 
the addition to TMP-SMX of monthly DP 
was well tolerated, which is a necessary 
precondition for any candidate prevention 
measure. In HIV-infected mothers, the 
risk of a mother transmitting HIV to her 
newborn and of adverse pregnancy out-
comes are substantially reduced by using 
antenatal antiretrovirals. In these women, 
enhanced antenatal antimalarial efforts 
will require additional multisite studies 
with well-tolerated antimalarials to further 
improve maternal and newborn health. 
Indeed, incipient studies with monthly 
DP in HIV-infected women in areas of 
Kenya and Malawi with higher burdens 
of malaria should provide compelling effi-
cacy and safety data in the coming years.
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